Palliative Care for Hematologic Malignancies

This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Define the evidence supporting the need of palliative/supportive care services
  • State the importance of integrating supportive care measures with curative treatment for the management of patients with hematological malignancies
Additional information

Supported by educational grants from:

  • Genentech USA, Inc.
  • Janssen Biotech, Inc., administered by Janssen Services, LLC.
  • Jazz Pharmaceuticals, Inc.
  • Millennium: The Takeda Oncology Company
  • Onyx Pharmaceuticals, Inc.
  • Sigma-Tau Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 0.25 Participation
  • 0.31 Nurse
  • 0.25 Pharmacist
  • 0.25 Physician
Course opens: 
Course expires: 

Susan G. Urba, MD
University of Michigan Comprehensive Cancer Center

Available Credit

  • 0.25 Participation
  • 0.31 Nurse
  • 0.25 Pharmacist
  • 0.25 Physician


Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing